c-RET
Os inibidores de c-RET têm como alvo o proto-oncogene RET (Rearranged during Transfection), que codifica uma tirosina quinase receptora envolvida no crescimento, diferenciação e sobrevivência celular. A ativação anormal da sinalização RET pode levar à proliferação celular descontrolada e à resistência à apoptose, contribuindo para o desenvolvimento de cânceres como o carcinoma medular da tireoide e o câncer de pulmão de células não pequenas. A inibição de c-RET pode induzir apoptose em células cancerígenas e é uma abordagem promissora na terapia oncológica direcionada. Na CymitQuimica, oferecemos uma variedade de inibidores de c-RET de alta qualidade para apoiar sua pesquisa em oncologia, transdução de sinais e apoptose.
Foram encontrados 60 produtos de "c-RET"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
TG-89
CAS:TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian andFórmula:C26H34N6O3SPureza:98.68%Cor e Forma:SolidPeso molecular:510.65Pz-1
CAS:Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.Fórmula:C26H26N6O2Pureza:99.89%Cor e Forma:SolidPeso molecular:454.52RET-IN-13
CAS:RET-IN-13: potent quinoline RET inhibitor; IC50 = 0.5 nM (WT), 0.9 nM (V804M); potential for RET-related tumor/intestinal disease research.Fórmula:C32H33F4N5O3Cor e Forma:SolidPeso molecular:611.63NSC194598
CAS:NSC194598 is a p53 DNA-binding inhibitor, demonstrating an in vitro IC50 of 180 nM and an in vivo range of 2-40 μM.Fórmula:C20H19N3OCor e Forma:SolidPeso molecular:317.38FHND5071
CAS:FHND5071, a potent and selective RET kinase inhibitor, exerts antitumor effects through the inhibition of RET autophosphorylation and may be utilized for tumorFórmula:C30H30D3N9OCor e Forma:SolidPeso molecular:538.66FLT3/ITD-IN-4
CAS:FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).Fórmula:C25H22N4O5Cor e Forma:SolidPeso molecular:458.47RET-IN-5
CAS:RET-IN-5 is a potent inhibitor of RET (IC50: 4.57 nM).Fórmula:C29H26FN9OCor e Forma:SolidPeso molecular:535.57RET-IN-24
CAS:RET-IN-24 (Compound 26) is a selective inhibitor of RET tyrosine kinase, demonstrating antitumor activity [1].Fórmula:C27H26F2N8OCor e Forma:SolidPeso molecular:516.55RET-IN-25
CAS:RET-IN-25 (compound 6b) is an anticancer RET kinase inhibitor that demonstrates efficacy against medullary thyroid carcinoma (MTC), exhibiting half-maximalFórmula:C22H17N3O5SCor e Forma:SolidPeso molecular:435.45RET-IN-17
CAS:RET-IN-17 inhibits RET kinase; may help in IBS pain and RET-activated cancers.Fórmula:C27H28F4N4O4Cor e Forma:SolidPeso molecular:548.53RET-IN-9
CAS:RET-IN-9 is a potent RET kinase inhibitor, potentially useful for studying RET-related diseases, including lung and thyroid cancer.Fórmula:C26H27N9OCor e Forma:SolidPeso molecular:481.55FHND5071 (1H)
CAS:FHND5071 (1H) is a selective inhibitor of RET (rearranged during transfection) tyrosine kinase. It shows potential for research applications in RET-driven cancers, such as thyroid and lung cancer.Fórmula:C30H33N9OCor e Forma:SolidPeso molecular:535.64LRRK2-IN-17
CAS:LRRK2-IN-17 is an orally active LRRK2 inhibitor with IC50 values of 3.5 nM for WT and 3.3 nM for G2019S, and it also inhibits RET kinase with an IC50 of 59 nM. LRRK2-IN-17 is utilized in research related to cancer and Parkinson's disease (PD).Fórmula:C18H18N8Cor e Forma:SolidPeso molecular:346.39RET-IN-10
CAS:RET-IN-10: Potent RET inhibitor, may treat congenital megacolon and tumors (Patent WO2021135938A1, compound 18).Fórmula:C29H28N8OSCor e Forma:SolidPeso molecular:536.65TAS05567
CAS:TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).Fórmula:C21H29N9O2Pureza:98%Cor e Forma:SolidPeso molecular:439.51RET-IN-30
CAS:RET-IN-30 (Compound 28) is a RET inhibitor that exhibits inhibitory activity against both wild-type RET and some of its mutants. It is capable of inhibiting the proliferation of A549 cells and demonstrates antitumor properties.Fórmula:C26H26FN5OCor e Forma:SolidPeso molecular:443.52RET-IN-7
CAS:RET-IN-7 exhibits strong inhibitory effects against RET kinase in vitro and shows significant efficacy in treating RET-driven tumor xenografts in mice throughFórmula:C22H24ClFN6O2Cor e Forma:SolidPeso molecular:458.92RET-IN-1
CAS:RET-IN-1 is a RET kinase inhibitor (IC50s: 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively).Fórmula:C29H31N9O3Pureza:98%Cor e Forma:SolidPeso molecular:553.61WF-47-JS03
WF-47-JS03: RET kinase inhibitor, crosses blood-brain barrier, 500x more selective for KDR, IC50: 1.7 nM in Ba/F3 cells, 5.3 nM in LC-2/ad lung cancer cells.
Fórmula:C30H38N6O2Cor e Forma:SolidPeso molecular:514.66Enbezotinib
CAS:Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.Fórmula:C21H21FN6O3Pureza:99.84%Cor e Forma:SolidPeso molecular:424.43Ref: TM-T62285
1mg77,00€5mg166,00€10mg253,00€25mg414,00€50mg567,00€100mg745,00€1mL*10mM (DMSO)182,00€
